combination therapies outperforming semaglutide Innovent and Lilly's Mazdutide Outperforms in Phase 3 DREAMS-3 Trial with Superior Glycemic Control and Weight Loss The evolving landscape of obesity

OR: 2.1

As GLP-1 weight-loss drug costs surge, most Connecticut employers cover them but impose conditions like prior authorization and lifestyle requirements to manage expenses, a strategy the state employee plan has used to slow spending growth.

Papers on the economics and business models of pharmacy benefits managers

Is Motility Something You Need to Stay on Long-Term

But if you dig into the state dashboards from The Center for Health Information and Analysis, or dig into the BCBS financial statements, or look at the UMMH's Form 990s, you might find some valuable context

Schedule a consultation today to learn more.